Cyclohexanehexol Therapy in Transgenic Models of Alzheimer's Disease

点击翻译按钮获取中文摘要

DESCRIPTION (provided by applicant): Senile plaques that contain beta amyloid (A¿) and neurofibrillary tangles (NFT) with phosphorylated tau are the pathological hallmarks of Alzheimer's disease (AD). Ass peptides, especially A¿42, are thought to play a key role in the pathogenesis of AD. We found that ibuprofen, a non-steroidal anti-inflammatory drug (NSAID) with A¿42- lowering effects, reduces Ass deposition, NFT and cognitive decline in a novel triple transgenic mouse model of AD (3xTg-AD) that develops both senile plaques and NFT. R-flurbiprofen, an enantiomer of the NSAID flurbiprofen that lowers A¿42 but lacks cyclooxygenase inhibition reduces A¿ burden in AD transgenic mice and is currently being tested in a phase III AD clinical trial. We found that oral R-flurbiprofen is well tolerated and detectable in transgenic mouse brain. Scyllo-inositol, an isomer of cyclohexanahexol, inhibits A¿ oligomers formation and, when orally administered to AD transgenicyc mice, reduces A¿ aggregation and deposition, and reduces cognitive decline. Importantly, scyllo-inositol is nontoxic, normally present in brain, and can be detected by magnetic resonance spectroscopy (MRS). A major goal of our proposal is to use the 3xTg-AD model and a double transgenic PSAPP model, that does not develop NFT but develops more widespread and rapid A¿ deposition, to assess the prophylactic and therapeutic effects of scyllo-inositol and a second isomer of cyclohexanahexol, myo-inositol, alone and in combination with R-flurbiprofen. We hypothesize that cyclohexanehexols will reduce the neurotoxicity of A¿ and improve the neurochemical profile and cognitive performance of transgenic mice by decreasing the oligomerization of A¿42 and that combination therapy with R-flurbiprofen, which reduces A¿ deposition through an entirely different mechanism of action, will have an additive therapeutic effect. Our preliminary studies show that we can detect a 3-4 fold increase in scyllo-inositol levels in the brains of transgenic mice treated with scyllo-inositol using MRS and that the treatment improves long-term memory in both transgenic mouse models. Preliminary studies using myo-inositol show that it is well tolerated in mice. The aims of the present proposal are: 1) To assess, the metabolic, histopathological, biochemical and cognitive profiles of double and triple transgenic mice treated with oral scyllo- or myo-inositol either before or after pathology has been established. Chiro-inositol, which has no effects on A¿, will be used as a control. Behavioral effects will be studied using radial arm water maze and biochemical and histological effects will be studied using western blot, ELISA, MRS and quantitative immunocytochemistry; 2) To assess whether combination therapy with R-flurbiprofen and the most effective cyclohexanahexol compound defined in aim 1 will have additive therapeutic effects using the parameters defined in aim 1. We will also perform serial MRS on mice at defined ages to assess the longitudinal effects of combination therapy on metabolic profiles. Our proposed research will investigate diagnostic methods and potential therapeutics integrating state of the art imaging, neuropathological and biochemical techniques to help design strategies to prevent and treat AD. PUBLIC HEALTH RELEVANCE: Alzheimer's disease is a relentlessly progressive, invariably fatal, disorder affecting millions of older Americans and costing the U.S. government billions of dollars in health care annually. In this proposal we will use a genetically modified mouse model that expresses human Alzheimer genes to study how we can treat the pathologies that are due to the accumulation of abnormal proteins in the brain. We will use therapeutic agents in living mice and monitor the disease progression with state-of-the-art imaging techniques and correlate findings with immunohistochemical findings. These studies will lay important groundwork for the future development of better approaches to detect and treat Alzheimer's disease.